Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization
Identifieur interne : 001E00 ( Istex/Corpus ); précédent : 001D99; suivant : 001E01Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization
Auteurs : Anumantha G. Kanthasamy ; Bang Q. Nguyen ; Daniel D. TruongSource :
- Movement Disorders [ 0885-3185 ] ; 2000-09.
English descriptors
- KwdEn :
Abstract
The sudden, brief, shock‐like, involuntary movements caused by active muscular contractions or inhibitions characterize myoclonus. It is manifested in a wide variety of pathologic conditions affecting the brain, spinal cord, or peripheral nerves, and is thought to be related to neuronal hyper‐excitability. The pathology, physiology, and pharmacology of myoclonus are not well understood as a result of the rarity of the disorder in people and the lack of a suitable animal model. Posthypoxic myoclonus is a major myoclonus syndrome which occurs as a result of severe cerebral ischemia/hypoxia. There has been tremendous interest in the development of a suitable animal model that reflects the etiology and clinical pathology of posthypoxic myoclonus. Recently, we have developed a new animal model of posthypoxic myoclonus in which rats were subjected to a mechanically induced cardiac arrest procedure. Herein, we describe the neurochemical, pharmacologic, and pathologic characteristics of this animal model of posthypoxic myoclonus.
Url:
DOI: 10.1002/mds.870150707
Links to Exploration step
ISTEX:9F594A31A342D2B1A5794ED146A3F6402F6B2266Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization</title><author><name sortKey="Kanthasamy, Anumantha G" sort="Kanthasamy, Anumantha G" uniqKey="Kanthasamy A" first="Anumantha G." last="Kanthasamy">Anumantha G. Kanthasamy</name><affiliation><mods:affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Nguyen, Bang Q" sort="Nguyen, Bang Q" uniqKey="Nguyen B" first="Bang Q." last="Nguyen">Bang Q. Nguyen</name><affiliation><mods:affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Truong, Daniel D" sort="Truong, Daniel D" uniqKey="Truong D" first="Daniel D." last="Truong">Daniel D. Truong</name><affiliation><mods:affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9F594A31A342D2B1A5794ED146A3F6402F6B2266</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/mds.870150707</idno><idno type="url">https://api.istex.fr/document/9F594A31A342D2B1A5794ED146A3F6402F6B2266/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E00</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization</title><author><name sortKey="Kanthasamy, Anumantha G" sort="Kanthasamy, Anumantha G" uniqKey="Kanthasamy A" first="Anumantha G." last="Kanthasamy">Anumantha G. Kanthasamy</name><affiliation><mods:affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Nguyen, Bang Q" sort="Nguyen, Bang Q" uniqKey="Nguyen B" first="Bang Q." last="Nguyen">Bang Q. Nguyen</name><affiliation><mods:affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Truong, Daniel D" sort="Truong, Daniel D" uniqKey="Truong D" first="Daniel D." last="Truong">Daniel D. Truong</name><affiliation><mods:affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2000-09">2000-09</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="31">31</biblScope><biblScope unit="page" to="38">38</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9F594A31A342D2B1A5794ED146A3F6402F6B2266</idno><idno type="DOI">10.1002/mds.870150707</idno><idno type="ArticleID">MDS870150707</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term><term>Cardiac arrest</term><term>DDT</term><term>Hypoxia</term><term>Movement disorder</term><term>Myoclonus</term><term>Serotonin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The sudden, brief, shock‐like, involuntary movements caused by active muscular contractions or inhibitions characterize myoclonus. It is manifested in a wide variety of pathologic conditions affecting the brain, spinal cord, or peripheral nerves, and is thought to be related to neuronal hyper‐excitability. The pathology, physiology, and pharmacology of myoclonus are not well understood as a result of the rarity of the disorder in people and the lack of a suitable animal model. Posthypoxic myoclonus is a major myoclonus syndrome which occurs as a result of severe cerebral ischemia/hypoxia. There has been tremendous interest in the development of a suitable animal model that reflects the etiology and clinical pathology of posthypoxic myoclonus. Recently, we have developed a new animal model of posthypoxic myoclonus in which rats were subjected to a mechanically induced cardiac arrest procedure. Herein, we describe the neurochemical, pharmacologic, and pathologic characteristics of this animal model of posthypoxic myoclonus.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anumantha G. Kanthasamy PhD</name><affiliations><json:string>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</json:string><json:string>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</json:string></affiliations></json:item><json:item><name>Bang Q. Nguyen MD</name><affiliations><json:string>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</json:string><json:string>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</json:string></affiliations></json:item><json:item><name>Daniel D. Truong MD</name><affiliations><json:string>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</json:string><json:string>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Myoclonus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Animal model</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Hypoxia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Movement disorder</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cardiac arrest</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Serotonin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>DDT</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The sudden, brief, shock‐like, involuntary movements caused by active muscular contractions or inhibitions characterize myoclonus. It is manifested in a wide variety of pathologic conditions affecting the brain, spinal cord, or peripheral nerves, and is thought to be related to neuronal hyper‐excitability. The pathology, physiology, and pharmacology of myoclonus are not well understood as a result of the rarity of the disorder in people and the lack of a suitable animal model. Posthypoxic myoclonus is a major myoclonus syndrome which occurs as a result of severe cerebral ischemia/hypoxia. There has been tremendous interest in the development of a suitable animal model that reflects the etiology and clinical pathology of posthypoxic myoclonus. Recently, we have developed a new animal model of posthypoxic myoclonus in which rats were subjected to a mechanically induced cardiac arrest procedure. Herein, we describe the neurochemical, pharmacologic, and pathologic characteristics of this animal model of posthypoxic myoclonus.</abstract><qualityIndicators><score>5.495</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792.24 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractCharCount>1037</abstractCharCount><pdfWordCount>3695</pdfWordCount><pdfCharCount>23889</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>150</abstractWordCount></qualityIndicators><title>Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization</title><genre><json:string>Serial article</json:string></genre><host><volume>15</volume><pages><total>8</total><last>38</last><first>31</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S1</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1002/mds.870150707</json:string></doi><id>9F594A31A342D2B1A5794ED146A3F6402F6B2266</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9F594A31A342D2B1A5794ED146A3F6402F6B2266/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9F594A31A342D2B1A5794ED146A3F6402F6B2266/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9F594A31A342D2B1A5794ED146A3F6402F6B2266/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2000</date></publicationStmt><notesStmt><note>Myoclonus Research Foundation</note><note>NIH‐SACNAS Biomedical Research</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization</title><author><persName><forename type="first">Anumantha G.</forename><surname>Kanthasamy</surname><roleName type="degree">PhD</roleName></persName><affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</affiliation><affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</affiliation></author><author><persName><forename type="first">Bang Q.</forename><surname>Nguyen</surname><roleName type="degree">MD</roleName></persName><affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</affiliation><affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</affiliation></author><author><persName><forename type="first">Daniel D.</forename><surname>Truong</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: The Parkinson and Movement Disorder Institute, 9900 Talbert Ave, #200, Fountain Valley, CA 92708, U.S.A.</p></note><affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</affiliation><affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2000-09"></date><biblScope unit="vol">15</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="31">31</biblScope><biblScope unit="page" to="38">38</biblScope></imprint></monogr><idno type="istex">9F594A31A342D2B1A5794ED146A3F6402F6B2266</idno><idno type="DOI">10.1002/mds.870150707</idno><idno type="ArticleID">MDS870150707</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The sudden, brief, shock‐like, involuntary movements caused by active muscular contractions or inhibitions characterize myoclonus. It is manifested in a wide variety of pathologic conditions affecting the brain, spinal cord, or peripheral nerves, and is thought to be related to neuronal hyper‐excitability. The pathology, physiology, and pharmacology of myoclonus are not well understood as a result of the rarity of the disorder in people and the lack of a suitable animal model. Posthypoxic myoclonus is a major myoclonus syndrome which occurs as a result of severe cerebral ischemia/hypoxia. There has been tremendous interest in the development of a suitable animal model that reflects the etiology and clinical pathology of posthypoxic myoclonus. Recently, we have developed a new animal model of posthypoxic myoclonus in which rats were subjected to a mechanically induced cardiac arrest procedure. Herein, we describe the neurochemical, pharmacologic, and pathologic characteristics of this animal model of posthypoxic myoclonus.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Myoclonus</term></item><item><term>Animal model</term></item><item><term>Hypoxia</term></item><item><term>Movement disorder</term></item><item><term>Cardiac arrest</term></item><item><term>Serotonin</term></item><item><term>DDT</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9F594A31A342D2B1A5794ED146A3F6402F6B2266/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley component found"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v15.1s</doi><titleGroup><title type="supplementTitle">Movement Disorders</title></titleGroup><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">S1</numbering><numbering type="supplement" number="S1">S1</numbering></numberingGroup><coverDate startDate="2000-09">September 2000</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="7" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870150707</doi><idGroup><id type="unit" value="MDS870150707"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2000 Movement Disorder Society</copyright><eventGroup><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.3 standalone mode:FullText" date="2012-02-28"></event><event type="firstOnline" date="2012-02-28"></event><event type="publishedOnlineFinalForm" date="2012-02-28"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">31</numbering><numbering type="pageLast">38</numbering></numberingGroup><correspondenceTo>The Parkinson and Movement Disorder Institute, 9900 Talbert Ave, #200, Fountain Valley, CA 92708, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870150707.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="6"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="0"></count></countGroup><titleGroup><title type="main" xml:lang="en">Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization</title><title type="short" xml:lang="en">NEUROCHEMICAL, PATHOLOGIC, AND PHARMACOLOGIC CHARACTERIZATION</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Anumantha G.</givenNames><familyName>Kanthasamy</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Bang Q.</givenNames><familyName>Nguyen</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Daniel D.</givenNames><familyName>Truong</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Myoclonus</keyword><keyword xml:id="kwd2">Animal model</keyword><keyword xml:id="kwd3">Hypoxia</keyword><keyword xml:id="kwd4">Movement disorder</keyword><keyword xml:id="kwd5">Cardiac arrest</keyword><keyword xml:id="kwd6">Serotonin</keyword><keyword xml:id="kwd7">DDT</keyword></keywordGroup><fundingInfo><fundingAgency>Myoclonus Research Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>NIH‐SACNAS Biomedical Research</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The sudden, brief, shock‐like, involuntary movements caused by active muscular contractions or inhibitions characterize myoclonus. It is manifested in a wide variety of pathologic conditions affecting the brain, spinal cord, or peripheral nerves, and is thought to be related to neuronal hyper‐excitability. The pathology, physiology, and pharmacology of myoclonus are not well understood as a result of the rarity of the disorder in people and the lack of a suitable animal model. Posthypoxic myoclonus is a major myoclonus syndrome which occurs as a result of severe cerebral ischemia/hypoxia. There has been tremendous interest in the development of a suitable animal model that reflects the etiology and clinical pathology of posthypoxic myoclonus. Recently, we have developed a new animal model of posthypoxic myoclonus in which rats were subjected to a mechanically induced cardiac arrest procedure. Herein, we describe the neurochemical, pharmacologic, and pathologic characteristics of this animal model of posthypoxic myoclonus.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>NEUROCHEMICAL, PATHOLOGIC, AND PHARMACOLOGIC CHARACTERIZATION</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization</title></titleInfo><name type="personal"><namePart type="given">Anumantha G.</namePart><namePart type="family">Kanthasamy</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</affiliation><affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bang Q.</namePart><namePart type="family">Nguyen</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</affiliation><affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel D.</namePart><namePart type="family">Truong</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Parkinson's and Movement Disorder Institute, Long Beach Memorial Medical Center, Long Beach, California, U.S.A.</affiliation><affiliation>Orange Coast Memorial Medical Center, Fountain Valley, California, U.S.A.</affiliation><description>Correspondence: The Parkinson and Movement Disorder Institute, 9900 Talbert Ave, #200, Fountain Valley, CA 92708, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2000-09</dateIssued><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">6</extent></physicalDescription><abstract lang="en">The sudden, brief, shock‐like, involuntary movements caused by active muscular contractions or inhibitions characterize myoclonus. It is manifested in a wide variety of pathologic conditions affecting the brain, spinal cord, or peripheral nerves, and is thought to be related to neuronal hyper‐excitability. The pathology, physiology, and pharmacology of myoclonus are not well understood as a result of the rarity of the disorder in people and the lack of a suitable animal model. Posthypoxic myoclonus is a major myoclonus syndrome which occurs as a result of severe cerebral ischemia/hypoxia. There has been tremendous interest in the development of a suitable animal model that reflects the etiology and clinical pathology of posthypoxic myoclonus. Recently, we have developed a new animal model of posthypoxic myoclonus in which rats were subjected to a mechanically induced cardiac arrest procedure. Herein, we describe the neurochemical, pharmacologic, and pathologic characteristics of this animal model of posthypoxic myoclonus.</abstract><note type="funding">Myoclonus Research Foundation</note><note type="funding">NIH‐SACNAS Biomedical Research</note><subject lang="en"><genre>Keywords</genre><topic>Myoclonus</topic><topic>Animal model</topic><topic>Hypoxia</topic><topic>Movement disorder</topic><topic>Cardiac arrest</topic><topic>Serotonin</topic><topic>DDT</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>S1</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>S1</number></detail><extent unit="pages"><start>31</start><end>38</end><total>8</total></extent></part></relatedItem><identifier type="istex">9F594A31A342D2B1A5794ED146A3F6402F6B2266</identifier><identifier type="DOI">10.1002/mds.870150707</identifier><identifier type="ArticleID">MDS870150707</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2000 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E00 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001E00 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:9F594A31A342D2B1A5794ED146A3F6402F6B2266
|texte= Animal model of posthypoxic myoclonus: II. Neurochemical, pathologic, and pharmacologic characterization
}}
| This area was generated with Dilib version V0.6.23. |  |